{"commentary":{"count":27,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":14,"podcast":8,"x_thread":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05197192\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT05197192","nct_id":"NCT05197192","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05197192. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Acalabrutinib plus Venetoclax plus Obinutuzumab plus (GAVe)","label":"GAVe-Arm","type":"EXPERIMENTAL"},{"description":"Obinutuzumab plus Venetoclax (GVe)","label":"GVe-Arm","type":"EXPERIMENTAL"}],"collaborators":["AstraZeneca"],"completion_date":{"date":"2028-05","type":"ESTIMATED"},"conditions":["Chronic Lymphocytic Leukemia"],"enrollment":{"count":202,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Obinutuzumab","type":"DRUG"},{"name":"Venetoclax","type":"DRUG"},{"name":"Acalabrutinib","type":"DRUG"}],"last_update":"2026-08-20","lead_sponsor":"German CLL Study Group","official_title":"A Prospective, Open-label, Multicentre, Randomized, Phase-3-trial of Acalabrutinib, Obinutuzumab and Venetoclax (GAVE) Compared to Obinutuzumab and Venetoclax (GVE) in Previously Untreated Patients With High Risk Chronic Lymphocytic Leukemia (CLL)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS)","timeFrame":"50 months after FPI"}],"references":[],"start_date":{"date":"2022-04-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL","url":"https://clinicaltrials.gov/study/NCT05197192"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05197192"}